A randomised double-blind controlled trial of s-ketamine versus placebo in conjunction with best pain management in neuropathic pain in cancer patients
- Conditions
- europathic pain in cancer patientsCancerNeuropathic pain in cancer patients
- Registration Number
- ISRCTN49116945
- Lead Sponsor
- Greater Glasgow and Clyde Health Board/Glasgow University (UK)
- Brief Summary
2018 Results article in https://www.ncbi.nlm.nih.gov/pubmed/29621378 results (added 18/02/2019)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 214
1. Aged greater than or equal to 18 years of age
2. Written informed consent
3. Neuropathic pain (as defined by the Leeds Assessment of Neuropathic Symptoms and Signs [LANSS]) that is related to underlying malignant disease
4. Neuropathic Pain greater than or equal to four on a zero to ten (Visual Analogue Scale [VAS]) and a McGill Sensory Scale Score greater than five
5. Will have had a trial of an adjuvant analgesic (gabapentin or amitriptyline)
1. Planned to receive chemotherapy or radiotherapy which may change pain during the period of the study
2. Diastolic Blood Pressure greater than 100 mmHg
3. History of seizures in last two years
4. Class I anti-arrhythmic drugs
5. Life expectancy less than two months
6. Patients who are actively hallucinating
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method